(Total Views: 507)
Posted On: 09/02/2020 12:24:38 PM
Post# of 208
$TSOI is one of the few biotech companies, producing allogeneic supercharged dendritic cells and mesenchymal stem cells JADICELL. I expect the company files for amendment of existing IND on STEMVACS to be repositioned for COVID-19 cellular treatment.
Also another amended IND is expected to be filed by TSOI on its JADICELL as stemcell therapy treatment of severely ill COVID-19 patients on Ventilator and ECOM before the end of September 2020. This would allow TSOI to create a path to commercialisation for QM, STEMVACS and JADICELL.
Remember TSOI already has initiated clinical trial with QUADRAMUNE for prevention of COVID-19 virus and is already underway.
Ref: 1. https://therapeuticsolutionsint.com/san-diego...ged-lungs/
2. https://therapeuticsolutionsint.com/therapeut...uadramune/
3. https://therapeuticsolutionsint.com/therapeut...ndication/
Also another amended IND is expected to be filed by TSOI on its JADICELL as stemcell therapy treatment of severely ill COVID-19 patients on Ventilator and ECOM before the end of September 2020. This would allow TSOI to create a path to commercialisation for QM, STEMVACS and JADICELL.
Remember TSOI already has initiated clinical trial with QUADRAMUNE for prevention of COVID-19 virus and is already underway.
Ref: 1. https://therapeuticsolutionsint.com/san-diego...ged-lungs/
2. https://therapeuticsolutionsint.com/therapeut...uadramune/
3. https://therapeuticsolutionsint.com/therapeut...ndication/
(0)
(0)
